[Skip to Content]
[Skip to Content Landing]
Views 84
Citations 0
Comment & Response
July 2019

Vaccination for the Prevention of Group B Streptococcus Infection in Nonpregnant Adults—Reply

Author Affiliations
  • 1Massachusetts General Hospital, Harvard Medical School, Boston
JAMA Intern Med. 2019;179(7):999. doi:10.1001/jamainternmed.2019.1587

In Reply Dauby’s comments highlight the active progress in group B Streptococcus (GBS) vaccine development. The study he cites by Buurman and colleagues,1 published the day after publication of the study by Francois Watkins and collagues2 and my accompanying Invited Commentary,3 describes Pfizer’s development and preclinical studies of a novel hexavalent capsular polysaccharide (CPS) conjugate vaccine (GBS6) for the prevention of neonatal GBS infections by maternal immunization.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×